Dopamine transporter imaging with fluorine-18-FPCIT and PET

Journal of Nuclear Medicine

Volumn 39, Issue 9, 1998, Pages 1521-1530

  Kazumata, Ken ^b   Dhawan, Vijay ^b   Chaly, Thomas ^b   Antonini, Angelo ^b   Margouleff, Claude ^b   Belakhlef, Abdelfatihe ^b   Neumeyer, John ^b   Eidelberg, David ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

Aging effect; Dopamine transporters; Fluorine 18 fluorinated N 3 fluoropropyl 2 carboxymethoxy 3 (4 iodophenyl) nortropane; Parkinson's disease; PET

Indexed keywords

DOPAMINE TRANSPORTER; FLUORINE 18; FLUORINE DERIVATIVE; N 3 FLUOROPROPYL 2 BETA CARBOXYMETHOXY 3 BETA (4 IODOPHENYL)NORTROPANE F 18; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DETERMINATION; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE LABELING; LIGAND BINDING; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; AGING; BRAIN; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TROPANES;

EID: 0031689041     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lundkvist C, Halldin C, Swahn CG, et al. [O-Methyl-11C] β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. Nucl Med Biol 1995;22;7:905-913.
2. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 1996;37:1129-1133.
3. Kaufmann MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum. Synapse 1991;49:43-49.
4. Niznik HB, Fogel EF, Fassos FF, et al. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991;56:192-198.
5. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
6. 123I] β-CIT: phamacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
7. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994;36:237-239.
8. Volkow ND, Ding YS, Fowler JS, et al. New PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med 1995;36:2162-2168.
9. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760-1765.
10. Laihinen AO, Rinne JO, Kjell A, et al. PET studies on brain monoamine transporters with carbon-11-β-CIT in Parkinson's disease. J Nucl Med 1995;36:1263-1267.
11. Neumeyer JL, Wang S, Gao Y, et al. N-ω-fluoroalkyl analogs of (1R)-2b-carbomethoxy-3b-(4-iodophenyl)-tropane (βCIT): radiotracer for PET and SPECT imaging of the dopamine transporters. J Med Chem 1994;37:1558-1561.
12. 123I]β-CIT) in nonhuman primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. Nucl Med Biol 1993;20: 597-606.
13. 123I] N-ω-2b-carboxy-3b-(4-iodophenyl)-nortropane esters in baboons. Nucl Med Biol 1995;22:211-219.
14. Kuikka JT, Bergstrom KA, Ahonen A, et al. Comparison of iodine-123-labeled 2β-carboxymethoxy-3β-(4-iodophenyl) tropane and 2β-carboxymethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356-360.
15. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-1181.
16. Eidelberg D, Takikawa S, Dhawan V, et al. Striatal 18F-DOPA uptake: absence of aging effect. J Cereb Blood Flow Metab 1993;13:881-888.
17. Kish SJ, Zhong XH, Hornykiewicz O, et al. Striatal DOPA decarboxylase in aging: disparity between postmortem and PET studies? Ann Neurol 1995;38:260-264.
18. Dhawan V, Ishikawa T, Patlak C, et al. Combined FDOPA and 3OMD PET studies in Parkinson's disease. J Nucl Med 1996;37:209-216.
19. Ishikawa T, Dhawan V, Chaly T, et al. The clinical significance of dopa decarboxylase activity in Parkinson's disease. J Nucl Med 1996;37:216-222.
20. Ishikawa T, Dhawan V, Chaly T, et al. Fluorodopa PET with an inhibitor of Catechol-o-methyltransferase: effect of the plasma 3-o-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 1996;16:854-863.
21. 18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with PET. Nucl Med Biol 1996;23:999-1004.
22. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747.
23. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratio without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16: 834-840.
24. Fahn S, Elton RL and the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease, vol. 2. Floral Park, NJ: Macmillan; 1987:293-304.
25. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994;35:1398-1406.
26. Hariz MI. Clinical study on the accuracy of the Laitinen CT-guidance system in functional stereotactic neurosurgery. Stereotact Funct Neurosurg 1991;56:109-128.
27. 82Rb-/PET studies of blood-brain-barrier permeability. Phys Med Biol 1988;33:61-74.
28. 123I labeled β-FP-CIT and β-CIT-FE metabolism measured in monkey and human plasma. Identification of two-labeled metabolites with HPLC. Hum Psychopharmacol 1996; 11:483-490.
29. Goodman MM, Keil R, Shoup TM, et al. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J Nucl Med 1997;38:119-126.
30. 125I]-epidepride. Brain Res 1993;609: 237-243.
31. Ichise M, Ballinger JR, Golan H, et al. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med 1996;37:513-520.
32. 18F]-cyclofoxy and PET. J Cereb Blood Flow Metab 1993;13:24-42.
33. Fearnley JM, Lees AJ. Aging. Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
34. De Keyser JD, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 1990;27:157-161.
35. Volkow ND, Ding YS, Fowler JS, et al. Dopamine transporters decrease with age. J Nucl Med 1996;37:554-559.
36. 123I] β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:579-598.
37. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
38. Marek KL, Seibyl JP, Zoghbi SS, et al. Iodine-123 β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.